Physician profile
Nathan Bibliowicz
NPI 1447593686
$16,302.15
in general payments reported to CMS, 2019-2025
38 companies · $3,471 in 2025
The $3,471 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $1,099 · 2021: $2,230 · 2022: $1,958 · 2023: $3,482 · 2024: $3,142 · 2025: $3,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,833 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,833.29 |
| Education | $261.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,327.69 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,787.81 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Sun Pharmaceutical Industries INC. | $1,154.39 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $1,115.22 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $1,102.09 | 2020-2025 | |
| Leo Pharma INC. | $852.98 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $830.85 | 2021-2025 | |
| Lilly USA, LLC | $776.83 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $682.02 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $632.47 | 2019-2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $536.20 | 2019-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $528.30 | 2023-2025 | Zoryve |
| Genzyme Corporation | $527.50 | 2021-2025 | |
| Ucb, INC. | $495.24 | 2020-2025 | Bimzelx, Cimzia |
| Amgen INC. | $476.03 | 2020-2025 | Otezla, Otezla |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $347.83 | 2020-2023 | Erivedge |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $341.22 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Galderma Laboratories, L.P. | $300.10 | 2019-2025 | Nemluvio, Oracea, Twyneo |
| Integra Lifesciences Corporation | $188.55 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Organon LLC | $183.53 | 2024-2025 | Vtama |
| Mayne Pharma Commercial LLC | $132.41 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $106.20 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $104.84 | 2021 | |
| Incyte Corporation | $104.21 | 2022-2025 | Opzelura |
| Allergan, INC. | $97.33 | 2019 | |
| Almirall LLC | $89.21 | 2022-2023 | Klisyri |
| Organogenesis INC. | $81.06 | 2023-2024 | Puraply |
| Biofrontera INC. | $71.12 | 2020-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Verrica Pharmaceuticals INC. | $66.34 | 2023-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.19 | 2023-2024 | Spevigo |
| Strata Skin Sciences, INC. | $38.23 | 2021-2024 | Xtrac |
| Botanix Sb INC | $37.10 | 2025 | Sofdra |
| Journey Medical Corporation | $27.09 | 2023 | |
| Smith+Nephew, INC. | $27.09 | 2022-2023 | Collagenase Santyl |
| Epi Health, LLC | $25.87 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $24.03 | 2023 | |
| Dermira, INC. | $19.60 | 2019 | |
| Merck Sharp & Dohme LLC | $19.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Bibliowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.